## **COMMITTEE REPORT**

## **MADAM PRESIDENT:**

The Senate Committee on Health and Provider Services, to which was referred Senate Bill No. 111, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

1	Page 1, delete lines 1 through 17, begin a new paragraph and insert:
2	"SECTION 1. IC 25-26-16.5 IS ADDED TO THE INDIANA CODE
3	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY
4	1, 2004]:
5	Chapter 16.5. Drug Regimens in Health Facilities
6	Sec. 1. This chapter applies to a health facility licensed under
7	IC 16-28.
8	Sec. 2. (a) As used in this chapter, "attending physician"
9	means a physician licensed under IC 25-22.5 who is responsible
10	for the ongoing health care of an individual who resides in a
1	health facility.
12	(b) The medical director of a health facility to which the
13	individual is admitted may not serve as the individual's attending
4	physician unless the medical director meets the requirements set
15	forth in subsection (a).
16	Sec. 3. As used in this chapter, "protocol" means a policy,
17	procedure, or protocol of a health facility concerning the
18	adjustment of a patient's drug regimen as allowed under this
19	chapter by a pharmacist licensed under this article.

1	Sec. 4. As used in this chapter, "therapeutic alternative"
2	means a drug product that:
3	(1) has a different chemical structure from;
4	(2) is of the same pharmacological or therapeutic class as;
5	and
6	(3) usually can be expected to have similar therapeutic
7	effects and adverse reaction profiles when administered to
8	patients in therapeutically equivalent doses as;
9	another drug.
10	Sec. 5. For purposes of this chapter, a pharmacist adjusts a
1	drug regimen if the pharmacist:
12	(1) changes the duration of treatment for a current drug
13	therapy;
14	(2) adjusts a drug's strength, dosage form, frequency of
15	administration, or route of administration;
16	(3) discontinues the use of a drug; or
17	(4) adds a drug to the treatment regimen.
18	Sec. 6. At the time an individual is admitted to a health facility
19	that has adopted a protocol under this chapter, the individual's
20	attending physician shall signify in writing in the form and
21	manner prescribed by the health facility whether the protocol
22	applies in the care and treatment of the individual.
23	Sec. 7. (a) A pharmacist may adjust the drug therapy regimen
24	of the individual under:
25	(1) the written authorization of the individual's attending
26	physician under section 6 of this chapter;
27	(2) the health facility's protocols; and
28	(3) this chapter.
29	(b) The pharmacist shall review the appropriate medical records
30	of the individual to determine whether the attending physician has
31	authorized the use of a specific protocol before the pharmacist
32	adjusts the individual's drug therapy regimen.
33	(c) Notwithstanding subsection (a), if a protocol involves
34	parenteral nutrition of the patient, the pharmacist shall
35	communicate with the attending physician to receive approval to
36	begin the protocol. The pharmacist shall document the
37	authorization of the attending physician to use the protocol
38	immediately in the individual's medical record.

Sec. 8. If a health facility elects to implement, revise, or renew

39

1	a protocol under this chapter, the health facility shall establish a
2	drug regimen review committee consisting of:
3	(1) the health facility's medical director;
4	(2) the health facility's director of nursing; and
5	(3) a consulting pharmacist licensed under this article;
6	for the implementation, revision, or renewal of a protocol.
7	Sec. 9. Except for the addition or deletion of authorized
8	physicians and pharmacists, a modification to a written protocol
9	requires the initiation of a new protocol.
10	Sec. 10. (a) A protocol of a health facility developed under this
11	chapter must be:
12	(1) based on clinical considerations; and
13	(2) reviewed by the health facility's drug regimen committee
14	at least quarterly.
15	(b) A protocol of a health facility developed under this chapter
16	may not:
17	(1) prohibit the attending physician from approving only
18	specific parts of a protocol; or
19	(2) provide for an adjustment to an individual's drug regimen
20	for the sole purpose of achieving a higher reimbursement for
21	the substituted drug therapy than what would have been
22	received for the original drug therapy ordered by the
23	attending physician.
24	Sec. 11. A protocol developed under this chapter must include
25	the following:
26	(1) The identification of:
27	(A) the individual whose drug regimen may be adjusted;
28	(B) the attending physician who is delegating the authority
29	to adjust an individual's drug regimen; and
30	(C) the pharmacist who is authorized to adjust the
31	individual's drug regimen.
32	(2) The attending physician's diagnosis of the individual's:
33	(A) condition; or
34	(B) disease state;
35	whose drug regimen may be adjusted.
36	(3) A statement regarding:
37	(A) the types and:
38	(i) categories; or
39	(ii) therapeutic classifications;

1	of medication, including the specific therapeutic
2	alternatives that may be substituted for a drug prescribed
3	by a physician;
4	(B) the minimum and maximum dosage levels within the
5	types and:
6	(i) categories; or
7	(ii) therapeutic classifications;
8	of medications described in clause (A);
9	(C) the dosage forms;
10	(D) the frequency of administration;
1	(E) the route of administration;
12	(F) the duration of the administration of the drug regimen
13	and any adjustment to the drug regimen; and
14	(G) exceptions to the application of the drug regimen or
15	the adjustment to the drug regimen;
16	for which the pharmacist may adjust the individual's drug
17	regimen.
18	(4) A requirement that:
19	(A) the individual's medical records be available to both
20	the individual's attending physician and the pharmacist;
21	and
22	(B) the procedures performed by the pharmacist relate to
23	a disease or condition for which the patient has been
24	under the attending physician's medical care.
25	Sec. 12. A protocol developed under this chapter that is
26	implemented for a Medicaid recipient must comply with any
27	statutes, regulations, and procedures under the state Medicaid
28	program relating to the preferred drug list established under
29	IC 12-15-35-28.
30	Sec. 13. If a protocol developed under this chapter allows a
31	pharmacist to substitute a therapeutic alternative for the drug
32	prescribed by the individual's attending physician, the attending
33	physician's authorization of the substitution is valid only for the
34	duration of the prescription or drug order.
35	Sec. 14. This chapter does not allow a pharmacist to substitute
36	a therapeutic alternative for the drug prescribed by the
37	individual's attending physician unless the substitution is
38	authorized by the attending physician under a valid protocol under

39

this chapter.

1	Sec. 15. The individual's attending physician:	
2	(1) shall review a protocol approved for a patient of the	
3	physician at least quarterly; and	
4	(2) may at any time modify or cancel a protocol by entering	
5	the modification or cancellation in the individual's medical	
6	record.	
7	Sec. 16. (a) Documentation of protocols must be maintained in	
8	a current, consistent, and readily retrievable manner.	
9	(b) After making an adjustment to an individual's drug	
10	regimen, the pharmacist shall notify the individual's attending	
11	physician of the adjustment not later than one (1) business day	
12	after the adjustment is made.	
13	Sec. 17. (a) This chapter does not modify the requirements of	
14	other statutes relating to the confidentiality of medical records.	
15	(b) This chapter does not make any other licensed health care	
16	provider liable for the actions of a pharmacist carried out under	
17	this section.	
18	Sec. 18. A pharmacist who violates this chapter is subject to	
19	discipline under IC 25-1-9.".	
20	Delete pages 2 through 3.	
	(Reference is to SB 111 as introduced.)	

and when so amended that said bill do pass.	
Committee Vote: Yeas 9, Nays 0.	
	Senator Miller, Chairperson